Search results.

Audit the accepted Thymosin Alpha-1 5 mg price change from $54.99 to $60.49, plus current matched-market range, availability, sources, and methodology.

Obesity and metabolic pipeline. GIP and GLP-1 receptor dual agonist · Once-weekly subcutaneous injection and once-daily oral tablet. 5 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

VK2735 and enicepatide are different investigational GLP-1/GIP dual agonists with no head-to-head trial. VK2735 is a Viking Therapeutics program being studied as both a weekly injection and daily tablet. Enicepatide, formerly CT-388, is Roche's signal-biased once-weekly injectable program. VK2735 has two 13-week Phase 2 formulation records and fully enrolled injectable Phase 3 trials. Enicepatide has a 48-week Phase 2 result and recruiting Phase 3 trials. Neither is FDA approved, and matching receptor labels do not make their doses, percentages, tolerability, or future products interchangeable.

VK2735 and retatrutide are separate investigational peptide programs with no randomized head-to-head trial. VK2735 activates GLP-1 and GIP receptors and is being developed as both a weekly injection and daily tablet. Retatrutide activates GIP, GLP-1, and glucagon receptors as a weekly injection. VK2735 has 13-week Phase 2 results and fully enrolled injectable Phase 3 trials without outcomes. Retatrutide has reported 80-week Phase 3 obesity results. Neither is FDA approved, and the available evidence cannot show that one is faster, stronger, safer, or better for an individual.

FDA-approved melanocortin medicine. Injection · Subcutaneous. NDA 210557 · FDA-approved prescription drug.

FDA-approved incretin medicine. Injection and tablets · Subcutaneous and oral. NDA 215256 · FDA-approved prescription drug.

Separate FDA-approved Wegovy, Zepbound, and Saxenda from Retatrutide, CagriSema, cagrilintide, Zenagamtide, MariTide, Survodutide, and other clinical programs.

Compare semaglutide with CagriSema, retatrutide, ecnoglutide, and other metabolic programs while preserving direct-trial, product, regulatory, and ClinicalTrials.gov registry boundaries.

Filter 15 source-linked trial results, then choose any two to diagnose shared randomization, result basis, duration, phase, population, route, masking, and source maturity.

Download 15 normalized, source-linked trial observations with duration, phase, route, population, comparator, estimand, alternate analysis, ClinicalTrials.gov enrollment, allocation, intervention model, masking, registry status, and outcome sources.

Learn how amino-acid chains become approved medicines, clinical candidates, compounded preparations, cosmetics, supplements, or research materials, and why those categories cannot be mixed.

Obesity and metabolic pipeline. GLP-1 + amylin receptor agonist · Once-daily oral or once-weekly subcutaneous. 24 matched ClinicalTrials.gov records with status, phase, posted-results, country, US state, and site-level recruitment context.

Amycretin, now called zenagamtide, and CagriSema are separate Novo Nordisk programs that both combine GLP-1 and amylin biology, but they have not been compared head to head. Zenagamtide is one investigational molecule being developed as a daily tablet and a weekly injection. CagriSema is a weekly fixed-dose injection containing two molecules, cagrilintide and semaglutide. CagriSema has completed pivotal Phase 3 trials and is under FDA review, while zenagamtide's current evidence is earlier and its Phase 3 development is underway. Neither is FDA approved.

Amycretin, now called zenagamtide, and retatrutide are separate investigational programs with no head-to-head trial. Zenagamtide activates GLP-1 and amylin receptors and is being developed as both a once-daily tablet and a once-weekly injection. Retatrutide is a once-weekly GIP, GLP-1, and glucagon triple agonist. Retatrutide has Phase 3 obesity topline results, while zenagamtide evidence spans earlier oral studies, Phase 2 oral and injectable data, and newer late-stage development records. Neither is FDA approved.

FDA-approved incretin medicine. Injection · Subcutaneous. NDA 217806 · FDA-approved prescription drug.